Literature DB >> 32773089

Labeling a TCO-functionalized single domain antibody fragment with 18F via inverse electron demand Diels Alder cycloaddition using a fluoronicotinyl moiety-bearing tetrazine derivative.

Zhengyuan Zhou1, Michael R Zalutsky1, Ganesan Vaidyanathan2.   

Abstract

Single domain antibody fragments (sdAbs) exhibit a rapid tumor uptake and fast blood clearance amenable for labeling with 18F (t½ = 110 min) but suffer from high kidney accumulation. Previously, we developed a method for 18F-labeling of sdAbs via trans-cyclooctene (TCO)-tetrazine (Tz) inverse electron demand Diel's Alder cycloaddition reaction (IEDDAR) that incorporated a renal brush border enzyme (RBBE)-cleavable linker. Although >15 fold reduction in kidney activity levels was achieved, tumor uptake was compromised. Here we investigate whether replacing the [18F]AlF-NOTA moiety with [18F]fluoronicotinyl would rectify this problem. Anti-HER2 sdAb 5F7 was first derivatized with a TCO-containing agent that included the RBBE-cleavable linker GlyLys (GK) and a PEG chain, and then subjected to IEDDAR with 6-[18F]fluoronicotinyl-PEG4-methyltetrazine to provide [18F]FN-PEG4-Tz-TCO-GK-PEG4-5F7 ([18F]FN-GK-5F7). For comparisons, a control lacking GK linker and 5F7 labeled using residualizing N-succinimidyl 3-guanidinomethyl-5-[125I]iodobenzoate (iso-[125I]SGMIB) also were synthesized. Radiochemical purity, affinity (KD) and immunoreactive fraction of [18F]FN-GK-5F7 were 99%, 5.4 ± 0.7 nM and 72.5 ± 4.3%, respectively. Tumor uptake of [18F]FN-GK-5F7 in athymic mice bearing subcutaneous SKOV3 xenografts (3.7 ± 1.2% ID/g and 3.4 ± 1.0% ID/g at 1 h and 3 h, respectively) was 2- to 3-fold lower than for co-injected iso-[125I]SGMIB-5F7 (6.9 ± 1.9 %ID/g and 8.7 ± 3.0 %ID/g). However, due to its 6-fold lower kidney activity levels, tumor-to-kidney ratios for [18F]FN-GK-5F7 were 3-4 times higher than those for co-injected iso-[125I]SGMIB-5F7 as well as those observed for the 18F conjugate lacking the RBBE-cleavable linker. Micro-PET/CT imaging of [18F]FN-GK-5F7 in mice with SKOV-3 subcutaneous xenografts clearly delineated tumor as early as 1 h with minimal activity in the kidneys; however, there was considerable activity in gallbladder and intestines. Although the tumor uptake of [18F]FN-GK-5F7 was unexpectedly disappointing, incorporating an alternative RBBE-cleavable linker into this labeling strategy may ameliorate this problem.
Copyright © 2020 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Fluorine-18; HER2; Inverse electron-demand Diels-Alder reaction; PET imaging; Renal brush border enzyme-cleavable linker; Single domain antibody fragment (VHH, Nanobody)

Mesh:

Substances:

Year:  2020        PMID: 32773089      PMCID: PMC7458057          DOI: 10.1016/j.bmc.2020.115634

Source DB:  PubMed          Journal:  Bioorg Med Chem        ISSN: 0968-0896            Impact factor:   3.641


  57 in total

1.  Efficient [(18)F]AlF Radiolabeling of ZHER3:8698 Affibody Molecule for Imaging of HER3 Positive Tumors.

Authors:  Chiara Da Pieve; Louis Allott; Carlos D Martins; Andrew Vardon; Daniela M Ciobota; Gabriela Kramer-Marek; Graham Smith
Journal:  Bioconjug Chem       Date:  2016-07-19       Impact factor: 4.774

2.  Preclinical Evaluation of 18F-Labeled Anti-HER2 Nanobody Conjugates for Imaging HER2 Receptor Expression by Immuno-PET.

Authors:  Ganesan Vaidyanathan; Darryl McDougald; Jaeyeon Choi; Eftychia Koumarianou; Douglas Weitzel; Takuya Osada; H Kim Lyerly; Michael R Zalutsky
Journal:  J Nucl Med       Date:  2016-02-18       Impact factor: 10.057

3.  Antibody Pretargeting Based on Bioorthogonal Click Chemistry for Cancer Imaging and Targeted Radionuclide Therapy.

Authors:  Aurélie Rondon; Françoise Degoul
Journal:  Bioconjug Chem       Date:  2020-01-06       Impact factor: 4.774

4.  Improving the Theranostic Potential of Exendin 4 by Reducing the Renal Radioactivity through Brush Border Membrane Enzyme-Mediated Degradation.

Authors:  Mingru Zhang; Orit Jacobson; Dale O Kiesewetter; Ying Ma; Zhantong Wang; Lixin Lang; Longguang Tang; Fei Kang; Hongzhang Deng; Weijing Yang; Gang Niu; Jing Wang; Xiaoyuan Chen
Journal:  Bioconjug Chem       Date:  2019-06-05       Impact factor: 4.774

5.  Fluorine-18 labeling of an anti-HER2 VHH using a residualizing prosthetic group via a strain-promoted click reaction: Chemistry and preliminary evaluation.

Authors:  Zhengyuan Zhou; Satish K Chitneni; Nick Devoogdt; Michael R Zalutsky; Ganesan Vaidyanathan
Journal:  Bioorg Med Chem       Date:  2018-03-15       Impact factor: 3.641

6.  Bioorthogonal Cycloadditions: Computational Analysis with the Distortion/Interaction Model and Predictions of Reactivities.

Authors:  Fang Liu; Yong Liang; K N Houk
Journal:  Acc Chem Res       Date:  2017-09-06       Impact factor: 22.384

7.  Astatine-211 labeled anti-HER2 5F7 single domain antibody fragment conjugates: radiolabeling and preliminary evaluation.

Authors:  Jaeyeon Choi; Ganesan Vaidyanathan; Eftychia Koumarianou; Choong Mo Kang; Michael R Zalutsky
Journal:  Nucl Med Biol       Date:  2017-09-19       Impact factor: 2.408

8.  Targeting breast carcinoma with radioiodinated anti-HER2 Nanobody.

Authors:  Marek Pruszynski; Eftychia Koumarianou; Ganesan Vaidyanathan; Hilde Revets; Nick Devoogdt; Tony Lahoutte; Michael R Zalutsky
Journal:  Nucl Med Biol       Date:  2012-11-15       Impact factor: 2.408

9.  Renal brush border enzyme-cleavable linkages for low renal radioactivity levels of radiolabeled antibody fragments.

Authors:  Hiromichi Akizawa; Mitsuo Imajima; Hirofumi Hanaoka; Tomoya Uehara; Satoshi Satake; Yasushi Arano
Journal:  Bioconjug Chem       Date:  2013-01-31       Impact factor: 4.774

Review 10.  Targeted Nanobody-Based Molecular Tracers for Nuclear Imaging and Image-Guided Surgery.

Authors:  Pieterjan Debie; Nick Devoogdt; Sophie Hernot
Journal:  Antibodies (Basel)       Date:  2019-01-11
View more
  2 in total

1.  Site-Specific and Residualizing Linker for 18F Labeling with Enhanced Renal Clearance: Application to an Anti-HER2 Single-Domain Antibody Fragment.

Authors:  Zhengyuan Zhou; Rebecca Meshaw; Michael R Zalutsky; Ganesan Vaidyanathan
Journal:  J Nucl Med       Date:  2021-02-26       Impact factor: 11.082

2.  Labeling single domain antibody fragments with 18F using a novel residualizing prosthetic agent - N-succinimidyl 3-(1-(2-(2-(2-(2-[18F]fluoroethoxy)ethoxy)ethoxy)ethyl)-1H-1,2,3-triazol-4-yl)-5-(guanidinomethyl)benzoate.

Authors:  Zhengyuan Zhou; Darryl McDougald; Rebecca Meshaw; Irina Balyasnikova; Michael R Zalutsky; Ganesan Vaidyanathan
Journal:  Nucl Med Biol       Date:  2021-06-11       Impact factor: 2.947

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.